Health-care shares were fairly flat in pre-market trade
In health-care stocks news, biopharmaceutical company Intercept
Pharmaceuticals Inc. (
) has been upgraded by analysts at Leerink Swann to an outperform
rating from market perform.
The firm also boosted its price target on the stock to $445 from
$270 a share, which represents a potential upside of 88% from its
Shares of ICPT have soared nearly 58% to $373.84 in Tuesday's
, moving within a 52-week range of $42.41 - $497. The gains follow
the company's earnings and pipeline update issued Monday night.
And, Opko Health (
) shares edged higher in Tuesday's pre-market session, after the
biopharmaceutical-and-diagnostics company late Monday reported a
narrower-than-expected Q2 loss and released successful top-line
results from the first pivotal phase 3 trial of its Rayaldee
treatment for secondary hyperparathyroidism in patients with stage
3 or 4 chronic kidney disease and vitamin D insufficiency.
OPK was up 2.9% at $9.63 in recent pre-market trading, in a
52-week range of $7.32 to $12.95.
Finally, Insys Therapeutics (
) is up after the company said it submitted a New Drug Application
to the U.S. FDA for its proprietary Dronabinol Oral Solution for
anorexia associated with weight loss in patients with AIDS; and
nausea and vomiting associated with cancer chemotherapy in patients
who have failed to respond adequately to conventional antiemetic
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.